Scientific Program 7 INTERNATIONAL CONGRESS OF THE GRS AND IGF SOCIETY

Transcription

7th INTERNATIONAL CONGRESS
OF THE GRS AND IGF SOCIETY
15-18 October 2014 • SINGAPORE
Scientific Program
15 October 2014, Wednesday
05:30 - 6:00 pm
Welcome Ceremony
Kok Onn Lee
John Kopchick
Terry Wood
Venue
16 October 2014, Thursday
Venue
Summit 2
PL
Plenary Lecture
Chair: Pinchas Cohen
Los Angeles, United States
Summit 2
06:00 - 07:00 pm
OL1
The William H Daughaday Lecture
Chair: Adrian Herington
Brisbane, Australia
Intervening in Ageing to Prevent Ageing-related Disease
Linda Partridge
London, United Kingdom
07:00 - 08:00 pm
Welcome Reception
Room 334
08:00 - 08:30 am
PL1.1
08:30 - 09:00 am
PL1.2
09:00 - 09:30 am
IGF-like Signaling of Drosophila
Marc Tatar
Rhode Island, United States
Effects of Growth Hormone Releasing Hormone on Visceral Fat,
Metabolic and Cardiovascular Indices in Human Studies
Steve Grinspoon
Massachusetts, United States
Break
Room 334
Venue
09:30 - 11:15 am
OR1
GH Clinical: Orals 1
Actions and Applications
Chair: Jens Otto Jørgensen
Aarhus, Denmark
Summit 2
09:30 - 11:15 am
OR2
IGF Basic: Orals 1
IGFBP
Chair: Briony Forbes
Adelaide, Australia
Christian Strasburger
Berlin, Germany
Venue
Room 331
Youngman Oh
Virginia, United States
09:30 am
OR1-1
GH Treatment Modulates Mortality in Adult onset GH Deficiency and
Discordant Socio-Economic Status is Apparent
Kirstine Stochholm
Aarhus University Hospital
Aarhus, Denmark
09:30 am
OR2-1
Impaired mTORC1 Activity Up-Regulates IGFBP-1 Synthesis During
Dietary Protein Restriction
Asako Takenaka
Meiji University
Kanagaw, Japan
09:45 am
OR1-2
Impairment of Anaerobic Capacity in Adults with GH Deficiency
Ken Ho
Princess Alexandra Hospital
Brisbane, Australia
10:00 am
OR1-3
The Molecular Mechanism of Dominantly Inherited Short Stature
Caused by GH Polymers
Zida Wu
Charité, Universitätsmedizin Berlin
Berlin, Germany
09:45 am
OR2-2
The Mitochondrial Peptide Humanin has Fasting Mimetic Activity
Leading to Suppression of Circulating IGF-I and Increases in
IGFBP-1 Levels
Jialin Xiao
University of Southern California
10:15 am
OR1-4
Successful GH Treatment for Severe Growth Failure in Pediatric Patients
with Anorexia Nervosa
Juliane Leger
Robert Debre Hospital
Paris, France
10:00 am
OR2-3
The Cardin-Weintraub Motif Present in IGFBP-2 is Required for Growth
and Function of the Mouse Brain
Nancy Schindler
Leibniz Institute for Farm Animal Biology (FBN)
Dummerstorf, Germany
10:30 am
OR1-5
Short Term Low Dose GH Therapy Improves Insulin Sensitivity But
Does Not Affect Cortisol Metabolism and Ectopic Fat Accumulation
in GH Deficient Adults
Kevin Yuen
Oregon Health & Science Univeristy
Portland, United States
10:15 am
OR2-4
Exogenous Administration of Protease-Resistant, Non Matrix-Binding
IGFBP-2 Inhibits Tumour Growth in a Murine Model of Breast Cancer
Cher-Lynn Soh
University of Adelaide
Adelaide, Australia
10:30 am
OR2-5
Linkage of Reproductive Development, Fat Metabolism and Life-Span
by the RGD-Motif of IGFBP-2 in Female Transgenic Mice
Andreas Hoeflich
Leibniz Institute for Farm Animal Biology (FBN)
Dummerstorf, Germany
10:45 am
OR1-6
Combination Medical Therapy for Acromegaly: The ACROSTUDY Experience
Beverly MK Biller
Massachusetts General Hospital
Boston, United States
10:45 am
OR2-6
Cyclic Glycine-Proline is a Regulator that Dynamically Controls IGF-1 Homeostasis through Altering IGF-1 Binding to IGFBP3
Jian Guan
University of Auckland
Auckland, New Zealand
Venue
Guided Poster Tour & Lunch
11:15 am - 12:45 pm GP1
GH Basic
Chairs:John Kopchick
Athens, United States
Venue
Room 334
Pinchas Cohen
GP1-1
Growth hormone targets expression of specific lipolytic genes to promote lipolysis of white adipose tissue
Yi Ying Law
Perdana University Graduate School of Medicine
Serdang, Malaysia
GP1-2
Autocrine human Growth Hormone suppression of E-CADHERIN via
p44/42 MAPK promotes Epithelial-to-Mesenchymal Transition (EMT)
of Colorectal Carcinoma cells
Jingjing Wang
National University of Singapore, Department of Pharmacology
Singapore
GP1-3
Role of growth hormone (GH) signaling pathways in the development of atherosclerosis
Mayumi Ishikawa
Nippon Medical School
Kawasaki, Japan
GP1-4
Mortality in patients with non-functioning pituitary adenoma with and
Late Breaking
without growth hormone replacement therapy. Acase-controlled study
in more than 400 patients
Daniel Olsson
Sahlgrenska University Hospital
Gothenburg, Sweden
11:15 am - 12:45 pm GP2
IGF Basic
Chair: Jeff Holly
Bristol, United Kingdom
Room 334
GP2-1
IGF-I Ameliorates Hepatic Fibrosis in Mouse Models of Non-Alcoholic Steatohepatitis and Cirrhosis via Inhibiting the Activity or Hepatic Stellate Cells
Hitoshi Nishizawa
Kobe University Graduate School of Medicine
Kobe, Japan
GP2-2
The Deubiquitinating Enzyme, USP9X Positively Regulates Insulin-like Growth
Factor (IGF)-Dependent Cell Growth by Inhibition of Degradation of IGF-I
Receptor (IGF-IR) and Insulin Receptor Substrate (IRS)-2 in Prostate Cancer Cells
Haruka Furuta
The University of Tokyo
Tokyo, Japan
GP2-3
The Role of the Insulin Receptor in Breast Cancer Progression
Derek LeRoith
Rambam Health Care Campus
Haifa, Israel
GP2-4
Insulin-like Growth Factor Binding Protein (IGFBP)-1 and its RGD Domain:
Favorable in Vivo Actions in Glucose Regulation
Natalie Haywood
University of Leeds
Leeds, United Kingdom
GP2-5
Hyperglycaemia Induces Chemo-Resistance of Breast Cancer Cells via Regulating IGFBP-2/Oestrogen Receptor (ERα) Interactions: Role of ERa Phosphorylation
Li Zeng
University of Bristol
GP2-6
Differential effects of IGFBP-6 on migration of two ovarian cancer cell lines
Leon Bach
Monash University
Melbourne, Australia
GP2-7
The IGF/IGFR pathway regulates axial patterning during early... The IGF/IGFR
Late Breaking
pathway regulates axial patterning during early neural development in mammal
Nozomu Takata
RIKEN, Center for Developmental Biology
Kobe, Japan
Venue
PL
Plenary Lecture
Chair: Shin Takahashi
Tokyo, Japan
Summit 2
12:45 - 01:15 pm
PL1.3
01:15 - 01:45 pm
PL1.4
Data on Efficacy of Long-acting Growth Hormone
Luo Xiaoping
Wuhan, China
Taking the Stress Out of Breast Cancer: Role of the IGFBPs
Claire Perks
02:00 - 05:00 pm
SY1
Growth Hormone Symposium
Supported by an unrestricted educational grant from Novo Nordisk
Session 1
Chairs:Pinchas Cohen
Venue
SY2
IGFs, Isulin and IGFBPs in Cancer
Chair: Rob Baxter
Sydney, Australia
02:00 pm
SY2-1
Insulin-like Growth Factor 2 mRNA Binding Proteins (IMP/IGF2BP) as
mRNA Safe Houses in Cancer and Development
Finn Nielsen
Copenhagen, Denmark
02:30 pm
SY2-2
The IRS proteins: Determinants of IGF-1R Signaling and Tumor Metabolism
Leslie Shaw
02:50 pm
SY1-3
Dosing and Monitoring GH Treatment in Children Born SGA
Juliane Leger
Paris, France
03:15 pm
SY1-4
Dosing and Monitoring GH treatment in Turner’s Syndrome
Toshiaka Tanaka
Tokyo, Japan
Break
Session 2
Chairs:Ken Ho
Brisbane, Australia
Jens S Christiansen
Aahus, Denmark
04:00 pm
SY1-5
GH Replacement in Adult GHD: Long-term Efficacy and Safety
Gudmundur Johansson
Gothenburg, Sweden
04:25 pm
SY1-6
Growth Hormone and Sarcopenia - Future Aspects
Michael Thorner
Charlottesville, United States
04:50 pm
SY1-7
Abuse of Growth Hormone
Berlin, Germany
05:15 pm
Room 331
Anne-Marie Kappelgaard
Copenhagen, Denmark
02:25 pm
SY1-2
Dosing and Monitoring GH Treatment in GH Deficient Children
Pinchas Cohen
Venue
Summit 2
02:00 pm
SY1-1
Metabolic Actions of GH Throughout Life-span
Jens Otto Jørgensen
Aarhus, Denmark
03:40 pm
Question & Answer
Room 334
03:00 pm
SY2-3
Obesity, Diabetes and Cancer Risk: Identifying Causal Factors
Emily Gallagher
Newark, United States
03:30 pm Break
Room 334
04:00 pm
SY2-4
IGFBP-2 in Cancer: From The Matrix to The Inside Job
Vince Russo
Room 331
Summit 2
04:30 pm
SY2-5
The G protein Estrogen Receptor (GPER) is involved in IGF-I/Insulin
Signaling in Cancer Cells
Marcello Maggiolini
Cosenza, Italy
05:00 pm
Question & Answer
05:15 - 06:15 pm
IGF General Meeting
Room 331
17 October 2014, Friday
Venue
PL
Plenary Lecture
Chair: Leon Bach
Summit 2
08:00 - 08:30 am
PL2.1
Not So Simple: Splicing News on Somatostatin and Ghrelin
Justo P Castaño
Córdoba, Spain
08:30 - 09:00 am
PL2.2
IGF-II and IGF2R in Cancer, Structure and Function
Bass Hassan
Oxford, United Kingdom
09:00 - 09:30 am
PL2.3
Nuclear IGF Receptors - A New Layer of Signalling Control
Haim Werner
Tel Aviv, Israel
09:30 - 10:00 am
Break
Room 334
Venue
10:00 - 11:30 am
OR3
GH Basic: Orals 1
Secretion and Actions
Chair: Ken Ho
Brisbane, Australia
Summit 2
10:00 - 11:30 am
OR4
IGF Clinical: Orals
Chair: Naomi Hizuka
Tokyo, Japan
Jorgen Isgaard
Gothenburg, Sweden
10:00 am
OR3-1 Spatial Learning, Memory and Signalling Crosstalk: Genomic and
Behavioural Analysis of Wild Type versus GH Modified (BGH and GHA) Mice
Amrita Basu
Ohio University
10:15 am
OR3-2 GH Enhances Spine Density in Amygdalar Neurons
Barbara Gisabella
Massachusetts Instutite of Technology
Cambridge, United States
10:30 am
OR3-3 Liver-specific (LiGHRKO) and fat-specific (FaGHRKO) growth hormone
receptor gene disrupted mice demonstrate paradoxical longevity and
provide evidence for GH stimulated liver/adipose tissue-crosstalk
Edward List
Ohio University
10:45 am
OR3-4 GH activated STAT5 is required for Induction of Beige Fat in Inguinal
White Adipose Tissue
Caroline Nelson
Univeristy of Queensland
Brisbane, Australia
11:00 am
OR3-5 NPY Neurons as a Critical Hypothalamic Node for the Control of GH
Release Relative to Food Intake
Frederik Steyn
Brisbane, Australia
11:15 am
OR3-6 Loss of Acyl-Ghrelin Signalling in Male Ghrelin-O-Acyltransferase
Knock-out Mice Results in Reduced Pulsatile GH Secretion and
a Derangement in GH Pulse Pattern
Teresa Xie
Brisbane, Australia
Derek LeRoith
Haifa, Israel
10:00 am
OR4-1 Randomised Controlled Clinical Trial Contrasting Current GH Doses
with Dose based on IGF-I titration in Children Born Small for
Gestational Age (NESGAS)
Rikke B Jensen
Univeristy of Cambridge
Cambridge, United Kingdom
10:15 am
OR4-2 Growth Hormone is a More Potent Growth Stimulating Hormone than
IGF-I; Clinical Perspective
Zvi Laron
Schneider Children’s Medical Center
Petah Tikva, Israel
10:30 am
OR4-3 Safety and Effectiveness of Increlex® Therapy in Children Enrolled
in the Increlex Growth Forum Database (IGFD) in Europe:
4-year Interim Results
Peter Bang
Linköping University
Linköping, Sweden
10:45 am
OR4-4 The Causal Role of IGFs and IGFBPs in Prostate Cancer:
a Mendelian Randomization Study
Jeff Holly
University of Bristol
11:00 am
OR4-5 IGF Bioactivity in Sera and Pleural Effusions from Patients Suspected
of Lung Cancer
Jan Frystyk
Aarhus University
Aarhus, Denmark
11:15 am
OR4-6 The Expression of Insulin-Like Growth Factor Type 1 Receptor (IGF1R)
is Increased in Obese Children
Carlos Martinelli
Ribeirão Preto Medical School-USP
Ribeirão Preto, Brazil
Venue
Room 331
Venue
Guided Poster Tour & Lunch
11:30 am - 01:15 pm GP3
GH Clinical Poster Tour
Chairs:Frederik Steyn
Brisbane, Australia
Venue
Rom 334
Gudmundur Johannsson
Gothenburg, Germany
GP3-1
Growth hormone (GH) replacement has a beneficial effect on glycosylated haemoglobin (HbA1c) levels in adult patients with GH deficiency (GHD) enrolled in the NordiNet® International Outcome Study (IOS)
Effie Pournara
Novo Nordisk Health Care AG
Zurich, Switzerland
GP3-2
Rosiglitazone treatment : Acromegaly Patients do not differ from normal
Type 2 Diabetics in their IGFBP-1 and Insulin dynamics with euglycemic glucose clamp
Mya Thway Tint
National University of Singapore
Singapore
GP3-3
The Diagnostic Accuracy of Pegvisomant-Primed Glucagon Stimulation Test (PV-GST) Compared To Insulin Tolerance (ITT) And Glucagon Stimulation (GST) Tests In Evaluating Adult Growth Hormone (GH) Reserve
Kevin Yuen
Oregon Health & Science Univeristy
GP3-4
Discordance Of Post-Surgical Nadir GH During OGTT And Serum IGF-I Levels
In Patients With Acromegaly
Izumi Fukuda
Tokyo Women’s Medical University
Tokyo, Japan
11:30 am - 01:15 pm GP4
IGF Clinical Poster Tour
Chair: Peter Bang
Linköping, Sweden
Room 334
GP4-1
Loss of PI 3-Kinase-Binding Protein PI3KAP/XB130 Suppresses Thyroid Function and Induces Enlargement of Thyroid Glands in Mice.
Daisuke Yamanaka
Nippon Medical School
Kawasaki, Japan
GP4-2
Effects of Heparin Administration on the Generation of IGFBP-4 Fragments
During PCI Treatment of ST-Elevation Myocardial Infarction Patients
Rikke Hjortebjerg
Aarhus University
Aarhus, Denmark
Epigenetic Analyses of the Insulin-like Growth Factor Binding Protein 1 Gene in Diabetes and Diabetic Nephropathy
Harvest Gu
Karolinska Institutet
Stockholm, Sweden
GP4-3
GP4-4
SGA Short Stature Bearing with a Novel Nonsense Mutation (p.W1219X)
in the IGF1R gene
Masanobu Fujimoto
Tottori University
Yonago, Japan
GP4-5
Circulating Levels of Insulin-like Growth Factor-1(IGF-I)/Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) in Obese Patients: the State of Type 2 Diabetes
Min Sun Kim
Chonbuk National University Medical School
Jeonju-si, Korea
GP4-6
Effects of GH/IGF-I Axis on Retinal Vascular Morphology: Retinal Vascular Morphology in Laron Syndrome
Z. Alev Ozon
Hacettepe University, Faculty of Medicine
Ankara, Turkey
GP4-7
Late Breaking
ProIGF-II not matureIGF-II promotes estrogen independent breast cancer growth and metastasis in a SCID and Nude mouse model: Differential
signallng mechanisms thru IGF and Insulin receptors and phosphorylation/
activation of estrogen and progesterone receptors.
Daisy De Leon
Loma Linda University
United States
Venue
PL
Plenary Lecture
Chair: Michael J Waters
Brisbane, Australia
Summit 2
01:15 - 01:45 pm
PL2.4
01:45 - 02:15 pm
PL2.5
02:15 - 02:45 pm
PL2.6
Prolactin, STAT5 and Prostate Cancer
Marja Tuili Nevulainen
Philadelphia, United States
02:45 - 03:15 pm
Break
Growth Hormone in Prader-Willi Syndrome
Cheri Deal
Montreal, Canada
mTOR Regulation and the Control of Cell and Organismal Growth
Joseph Avruch
Room 334
Venue
03:15 - 04:45 pm
OR5
GH Basic Orals 2:
Prolactin, Signalling & Cancer
Chair: Peter Lobie
Singapore
Summit 2
03:15 - 04:45 pm
OR6
IGF Basic: Orals
Physiology
Chair: Rosemary O’Connor
Cork, Ireland
Jan Frustuk
Aarhus, Denmark
03:30 pm
OR5-2 Rabbits are a Suitable Animal Model for the Pre-Clinical Development
of Growth Hormone Agonists and Antagonists
Max Bielohuby
Medizinische Klinik und Poliklinik IV
München, Germany
Terresa Wood
03:30 pm
OR6-2 IRS-1 Promotes Embryonic Growth of Zebrafish through IGF-IR Signal-
Dependent and Independent Mechanisms in Response to Developmental Stages and Environmental Oxygen Availability
Hirayasu Kamei
Tokyo, Japan
03:45 pm
OR5-3 A GH Antagonist Fusion with GH Binding Protein is Biologically Active,
Shows Delayed Clearance and Inhibits Growth in a Rabbit Model
Ian Wilkinson
University of Sheffield
Sheffield, United Kingdom
03:45 pm
OR6-3 Early Postnatal Nutritional Programming of Growth Involves GHRH
Neurons Axon Growth Stimulation by Leptin & IGF-I
Laurent Kappeler
Inserm
Paris, France
04:00 pm
OR5-4 The Choice of hGH Receptor Signalling Pathway Determines Longevity
Yash Chhabra
Institute for Molecular Bioscience, University of Queensland
Brisbane, Australia
04:15 pm
OR5-5 Autocrine hGH Stimulated miRNA 96-182-183 Cluster Promotes
Epithelial-Mesenchymal Transition and Invasion in Breast Cancer
Weijie Zhang
University of Science and Technology of China/Hefei National Laboratory
for Physical Sciences at Microscale
Hefei, China
04:00 pm
OR6-4 Sustained IGF-II Production is Necessary for Adult Neurogenesis
Steven W. Levison
Rutgers University
04:15 pm
OR6-5 Sexual Dimorphism of Insulin like Growth Factor I in Exercise
V.A. Munive Herrera
Cajal Institute
Madrid, Spain
04:30 pm
OR6-6 Dermal Fibroblast Secreted IGF-I Protects Skin Keratinocytes
Against Ultraviolet B Radiation Induced Damage
D.R. Van Lonkhuyzen
Institute for Health and Biomedical Innovation
Kelvin Grove, Australia
04:30 pm
OR5-6 Amplified Stem/Progenitor Cells in a Mouse Model of Prostate
Tumorigenesis Induced by Autocrine Prolactin
L Sackmann Sala
Inserm
Paris, France
GRS General Assembly
Room 331
03:15 pm
OR6-1
Dicarba Modification of Insulin Peptides Results in Lower Mitogenic
Activity Signaled via IGF-1R and IR than Insulin
Shee Chee Ong
Flinders University
Adelaide, Australia
03:15 pm
OR5-1 Mechanism of Activation of JAK2 by Growth Hormone
Michael J Waters
University of Queensland
Brisbane, Australia
04:45 - 05:45 pm
Venue
Summit 2
07:00 - 10:00 pm
Congress Dinner
18 October 2014, Saturday
Venue
PL
Plenary Lecture
Chair: Beverly MK Biller
Boston, United States
Summit 2
08:00 - 08:30 am
PL3.1
08:30 - 09:00 am
PL3.2
The Louis E Underwood Lecture:
Two Years in Growth Hormone
Berlin, Germany
09:00 - 09:30 am
Break
The Francesco Minuto Lecture:
Two Years in IGF / IGFBPs
Rob Baxter
Sydney, Australia
Room 334
Venue
09:30 - 11:30 am
OR7
GH Clinical: Orals 2
Long Acting GH
Chair: Martin Bidlingmaier
Munich, Germany
Summit 2
Venue
Jens Christiansen
Aarhus, Denmark
09:30 am
OR7-1 A Reversible Albumin-binding GH Derivative Possesses a Promising
Once-weekly Treatment Profile and is Well Tolerated in Adult Subjects
with GH Deficiency
Michael Rasmussen
Novo Nordisk Global Development
Søborg, Denmark
10:45 am
OR7-6
Late Breaking
Safety and Efficacy of ARX201: Six Month Dose-Ranging Study of a
Novel Long-acting Pegylated Growth Hormone in Young Adults with
Growth Hormone Deficiency
Douglas Axelrod
DW Axelrod Consultancy
Rancho Santa Fe, United States
09:45 am
OR7-2 The MOD-4023 Story: A Long Acting GH From Proof of Concept in Animal Models to GH Deficient Populations in Clinical Studies (Adult and Pediatric)
Gili Hart
OPKO Biologics
Nes Ziona, Israel
11:00 am
OR7-7
Late Breaking
Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: A phase III, multicenter, randomized study (PAOLA)
Maria Fleseriu
Oregon Health Science University
11:15 amOR7-8
Late Breaking
A Phase II Randomised, Open-Label, ParallelGroup Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of TwoSubcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly
Peter Trainer
The Christie NHS Foundation Trust
Manchester, United Kingdom
10:00 am
OR7-3 Safety and Efficacy Results of a 6 month, Randomized Multi-Center
Trial of a Long Acting rhGH (VRS-317) in Naive to Treatment,
Pre-Pubertal Children with GH Deficiency
George M Bright
Versartis, Inc.
Redwood City, United States
10:15 am
OR7-4
Late Breaking
A Phase 2, six-month dose-response study to investigate TransCon hGH,
a long-acting hGH, in treatment naïve children with idiopathic Growth
Hormone Deficiency (IGHD)
Pierre Chatelain
Université Claude Bernard Lyon 1
Bron Cedex, France
10:30 am
OR7-5
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TV-1106,
a New Long-acting Treatment for GH Deficiency
Merav Bassan
Teva Pharmaceuticals
Netanya, Israel
09:30 - 11:30 am
OR8
IGF Basic: Orals
Cancer
Chair: Emily Gallagher
Venue
Venue
Room 331
Daisy De Leon
California, United States
09:30 am
OR8-1 Insulin Receptor Substrate (IRS)-1 Interacts with Protein Arginine
Methyltransferase 5 (PRMT5), Emerging as a Novel Regulator of
Alternative Pre-mRNA Splicing
Atsufumi Ozoe
Tokyo, Japan
09:45 am
OR8-2 Insulin-like Growth Factor Receptor Inhibition in Mammary Epithelium
Enhances Wnt1-Mediated Tumors, Canonical Wnt Signaling and IGF-II/
Insulin-Receptor A Expression
Teresa L. Wood
NJMS Cancer Center, Rutgers University
10:00 am
OR8-3 Role of Deubiquitinase USP7 in Signalling through IGF-1R
Claire Worrall
Karolinska Institutet
Stockholm, Sweden
10:15 am
OR8-4 A Novel Antisense Long Noncoding RNA Within the IGF1R Gene Locus
is Imprinted in Hematopoietic Malignancies
Andrew Hoffman
Stanford University and VA Palo Alto Medical Center
Palo Alto, United States
10:30 am
OR8-5 Novel Mechanisms by which Nedd4-IRS-2 Complexes Enhance IGF-I signals,
and their Roles in IGF-I Action in Prostate Cancer Cell Proliferation
Tashiaki Fukushima
Hiroshima University
Hiroshima, Japan
10:45 am
OR8-6 The Anti-IGF Signaling Agents Increase the Efficacy of Trabectedin in
Ewing Sarcoma
Cecilia Garofalo
Ortopaedic Rizzoli Institute
Bologna, Italy
11:00 am
OR8-7
Insulin Like Growth Factor-II (IGF-II) regulates mitochondrial phenotype, Late Breaking
metabolism and DNA content to prevent apoptosis and to increase energy production efficiency promoting a more aggressive and chemo resistant
breast cancer disease
Daisy De Leon
LLUSM
Loma Linda, United States
11:15 am
OR8-8
Serum IGF-I measured longitudinally during pre-school years - relation to
Late Breaking
gender, body size, and nutrition such as essential fatty acids and vitamin D
Jovanna Dahlgren
Göteborg Pediatric Growth Research Center
Sweden
11:30 - 12:15 pm
Award and Closing Ceremony Kok Onn Lee
Singapore
Summit 2
Haim WernerTel Aviv
Israel
12:30 am - 13:30 pm Lunch
Room 334

Scientific Program 7 INTERNATIONAL CONGRESS OF THE GRS AND IGF SOCIETY

Transcription

Similar documents